EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study

Stefano Tancredi, Arnaud Chiolero, Cornelia Wagner, Moa Lina Haller, Patricia Chocano-Bedoya, Natalia Ortega, Nicolas Rodondi, Laurent Kaufmann, Elsa Lorthe, Hélène Baysson, Silvia Stringhini, Gisela Michel und 25 weitere

Infection · 2023-10 · 51 (5) · 1453-1465

DOI: 10.1007/s15010-023-02011-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infection, online erschienen am 04.03.2023. Verfasst von Stefano Tancredi und 36 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Laboratory (#PopHealthLab), University of Fribourg, Route Des Arsenaux 41, 1700, Fribourg, Switzerland. stefano.tancredi@unifr.ch. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Fribourg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We aimed to assess the seroprevalence trends of SARS-CoV-2 antibodies in several Swiss cantons between May 2020 and September 2021 and investigate risk factors for seropositivity and their changes over time.

Methods

We conducted repeated population-based serological studies in different Swiss regions using a common methodology. We defined three study periods: May–October 2020 (period 1, prior to vaccination), November 2020–mid-May 2021 (period 2, first months of the vaccination campaign), and mid-May–September 2021 (period 3, a large share of the population vaccinated). We measured anti-spike IgG. Participants provided information on sociodemographic and socioeconomic characteristics, health status, and adherence to preventive measures. We estimated seroprevalence with a Bayesian logistic regression model and the association between risk factors and seropositivity with Poisson models.

Results

We included 13,291 participants aged 20 and older from 11 Swiss cantons. Seroprevalence was 3.7% (95% CI 2.1–4.9) in period 1, 16.2% (95% CI 14.4–17.5) in period 2, and 72.0% (95% CI 70.3–73.8) in period 3, with regional variations. In period 1, younger age (20–64) was the only factor associated with higher seropositivity. In period 3, being aged ≥ 65 years, with a high income, retired, overweight or obese or with other comorbidities, was associated with higher seropositivity. These associations disappeared after adjusting for vaccination status. Seropositivity was lower in participants with lower adherence to preventive measures, due to a lower vaccination uptake.

Conclusions

Seroprevalence sharply increased over time, also thanks to vaccination, with some regional variations. After the vaccination campaign, no differences between subgroups were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansSeroepidemiologic StudiesBayes TheoremSARS-CoV-2Antibodies, Viral

Stichwörter der Autor:innen

COVID-19 pandemicEpidemiologyPublic healthSARS-CoV-2SeroprevalenceSurveillance

Substanzen

Antibodies, Viral

Autor:innen und Institutionen

  • Population Health Laboratory (#PopHealthLab), University of Fribourg, Route Des Arsenaux 41, 1700, Fribourg, Switzerland. stefano.tancredi@unifr.ch.
  • Population Health Laboratory (#PopHealthLab), University of Fribourg, Route Des Arsenaux 41, 1700, Fribourg, Switzerland.
  • School of Population and Global Health, McGill University, Montreal, Canada.
  • Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
  • Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Cantonal Public Health Service of the Canton of Neuchâtel, Neuchâtel, Switzerland.

Förderung

  • University of Fribourg

Zitieren

APA

Tancredi, S., Chiolero, A., Wagner, C., Haller, M. L., Chocano-Bedoya, P., Ortega, N., Rodondi, N., Kaufmann, L., Lorthe, E., Baysson, H., Stringhini, S., Michel, G., Lüdi, C., Harju, E., Frank, I., Imboden, M., Witzig, M., Keidel, D., Probst-Hensch, N., …, & Corona Immunitas Research Group (2023). Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study. Infection, 51(5), 1453-1465. https://doi.org/10.1007/s15010-023-02011-0

Vancouver

Tancredi S, Chiolero A, Wagner C, Haller ML, Chocano-Bedoya P, Ortega N, et al. Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study. Infection. 2023;51(5):1453-1465. doi:10.1007/s15010-023-02011-0

BibTeX
@article{Tancredi2023,
  author = {Tancredi, Stefano and Chiolero, Arnaud and Wagner, Cornelia and Haller, Moa Lina and Chocano-Bedoya, Patricia and Ortega, Natalia and Rodondi, Nicolas and Kaufmann, Laurent and Lorthe, Elsa and Baysson, Hélène and Stringhini, Silvia and Michel, Gisela and Lüdi, Chantal and Harju, Erika and Frank, Irene and Imboden, Medea and Witzig, Melissa and Keidel, Dirk and Probst-Hensch, Nicole and Amati, Rebecca and Albanese, Emiliano and Corna, Laurie and Crivelli, Luca and Vincentini, Julia and Gonseth Nusslé, Semira and Bochud, Murielle and D'Acremont, Valérie and Kohler, Philipp and Kahlert, Christian R and Cusini, Alexia and Frei, Anja and Puhan, Milo A and Geigges, Marco and Kaufmann, Marco and Fehr, Jan and Cullati, Stéphane and Corona Immunitas Research Group, Corona Immunitas Research Group},
  title = {Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study},
  journal = {Infection},
  year = {2023},
  volume = {51},
  number = {5},
  pages = {1453--1465},
  doi = {10.1007/s15010-023-02011-0}
}
Kostenlos starten →